Aduro BioTech Inc (NASDAQ:ADRO) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 6,766,441 shares, a decrease of 2.0% from the February 28th total of 6,905,941 shares. Based on an average trading volume of 374,861 shares, the days-to-cover ratio is currently 18.1 days.
In other news, insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 9th. The stock was sold at an average price of $10.96, for a total value of $274,000.00. Following the transaction, the insider now owns 54,804 shares of the company’s stock, valued at $600,651.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stephen T. Isaacs sold 27,273 shares of the stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $11.35, for a total value of $309,548.55. Following the sale, the insider now owns 129,473 shares of the company’s stock, valued at approximately $1,469,518.55. The disclosure for this sale can be found here. In the last three months, insiders sold 95,546 shares of company stock worth $1,037,595. 6.50% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of ADRO. Quantitative Systematic Strategies LLC bought a new stake in shares of Aduro BioTech during the first quarter worth about $145,000. Fox Run Management L.L.C. bought a new stake in shares of Aduro BioTech during the first quarter worth about $202,000. Daiwa SB Investments Ltd. bought a new stake in shares of Aduro BioTech during the first quarter worth about $153,000. Creative Planning raised its stake in shares of Aduro BioTech by 73.9% in the first quarter. Creative Planning now owns 15,000 shares of the biotechnology company’s stock worth $161,000 after buying an additional 6,375 shares during the period. Finally, Foundry Partners LLC raised its stake in shares of Aduro BioTech by 46.6% in the first quarter. Foundry Partners LLC now owns 113,575 shares of the biotechnology company’s stock worth $1,221,000 after buying an additional 36,123 shares during the period. Institutional investors and hedge funds own 35.52% of the company’s stock.
Shares of Aduro BioTech (NASDAQ:ADRO) traded up 0.54% during midday trading on Thursday, reaching $9.35. The company’s stock had a trading volume of 80,171 shares. Aduro BioTech has a one year low of $7.26 and a one year high of $16.43. The company’s market capitalization is $635.78 million. The stock’s 50-day moving average is $10.38 and its 200-day moving average is $11.49.
Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Wednesday, March 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.04. The company earned $3.88 million during the quarter, compared to analyst estimates of $3.83 million. Aduro BioTech had a negative net margin of 72.04% and a negative return on equity of 23.45%. On average, equities analysts expect that Aduro BioTech will post ($1.53) earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. Roth Capital reiterated a “buy” rating and set a $17.00 target price on shares of Aduro BioTech in a research report on Tuesday, March 7th. Canaccord Genuity set a $30.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, March 2nd. Finally, FBR & Co restated a “buy” rating and set a $23.00 price target on shares of Aduro BioTech in a report on Tuesday, March 7th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $21.00.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/04/20/short-interest-in-aduro-biotech-inc-adro-declines-by-2-0-updated.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.